Cargando…
Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
The dawn of the biologic era has been an exciting period for clinical research and patient care in rheumatoid arthritis (RA). Targeted biologic therapies have changed the outcome of this disease and made remission a realistic outcome for many patients. Tocilizumab (TCZ, Actemra(®)), is a humanized m...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990387/ https://www.ncbi.nlm.nih.gov/pubmed/21116333 http://dx.doi.org/10.2147/DDDT.S14099 |